<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00153634</url>
  </required_header>
  <id_info>
    <org_study_id>BURNS03A0</org_study_id>
    <nct_id>NCT00153634</nct_id>
  </id_info>
  <brief_title>Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)</brief_title>
  <official_title>Standard vs. Biofilm Susceptibility Testing in CF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized multi-center clinical trial to compare the microbiological efficacy,&#xD;
      clinical efficacy, and safety of using standard versus biofilm susceptibility testing of P.&#xD;
      aeruginosa sputum isolates to guide antibiotic selection for treatment of airway infection in&#xD;
      clinically stable patients with CF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were screened to determine eligibility and to obtain a sputum culture. Eligible&#xD;
      patients were randomized to either the standard or biofilm study arm. Antibiotic selection&#xD;
      was performed centrally according to a standard algorithm using the susceptibility test&#xD;
      results of the assigned study arm. On Day 0, patients were started on a 14-day course of two&#xD;
      antibiotics as selected per protocol. Antibiotics were administered intravenously (IV) and/or&#xD;
      orally. A follow-up phone call or visit occurred on Day 7. An end of treatment visit was&#xD;
      conducted after completion of antibiotic therapy. A total of 39 patients were randomized.&#xD;
      Many screened patients were ineligible for randomization based on microbiology results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiological efficacy: Change in P. aeruginosa density</measure>
    <time_frame>from enrollment (up to day -21) to end of treatment (day 12-14)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy: Pre- to post-treatment change in FEV1</measure>
    <time_frame>from initiation (day 0) to end of treatment (day 12-14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse events, including new onset of acute pulmonary exacerbation and/or the need to change antibiotic therapy during the treatment period</measure>
    <time_frame>from enrollment (up to day -21) to end of treatment (day 12-14)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility: Average costs and time per assay; rate of patient withdrawal because resistance patterns preclude randomization; self-reported technician satisfaction</measure>
    <time_frame>during active enrollment (March 2004-November 2007)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antibiotic regimen assignment based on biofilm susceptibility test results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antibiotic regimen assignment based on conventional susceptibility test results</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV amikacin</intervention_name>
    <description>5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PO azithromycin</intervention_name>
    <description>250 mg once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV ceftazidime</intervention_name>
    <description>50 mg/kg every 8 hours, up to 2 grams every 8 hours</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PO ciprofloxacin</intervention_name>
    <description>500 mg every 12 hours if weight &lt;50 kg 750 mg every 12 hours if weight ≥50 kg</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV meropenem</intervention_name>
    <description>40 mg/kg every 8 hours, up to 2 grams every 8 hours</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV piperacillin-tazobactam</intervention_name>
    <description>100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV ticarcillin-clavulanate</intervention_name>
    <description>100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV tobramycin</intervention_name>
    <description>2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of CF based on the following: sweat chloride &gt; 60 mEq/L (by quantitative&#xD;
             pilocarpine iontophoresis), or genotype with 2 identifiable mutations consistent with&#xD;
             CF; and one or more clinical features consistent with CF.&#xD;
&#xD;
          -  Age ≥ 14 years (changed from ≥ 18 years by protocol amendment).&#xD;
&#xD;
          -  Able to expectorate sputum at screening.&#xD;
&#xD;
          -  History of persistent positivity for P. aeruginosa on respiratory culture (at least&#xD;
             three positive oropharyngeal (OP), sputum and/or bronchoscopy cultures in the 24&#xD;
             months prior to screening).&#xD;
&#xD;
          -  Able to reproducibly perform pulmonary function testing.&#xD;
&#xD;
          -  Clinically stable at screening, with no evidence of pulmonary exacerbation.&#xD;
&#xD;
          -  Written informed consent provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sputum culture negative for P. aeruginosa or density less than 10E5 CFU/gm at&#xD;
             screening.&#xD;
&#xD;
          -  Sputum culture positive for B. cepacia at screening.&#xD;
&#xD;
          -  Presence of P. aeruginosa in sputum with off-scale resistance to all antibiotics by&#xD;
             either method of susceptibility testing at screening. (changed from multiply-resistant&#xD;
             P. aeruginosa by protocol amendment)&#xD;
&#xD;
          -  History of B. cepacia positive respiratory culture within 24 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Hospitalization or treatment for a pulmonary exacerbation within 2 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Administration of parenteral anti-pseudomonal antibiotics within 2 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Treatment with oral or inhaled anti-pseudomonal antibiotics, or azithromycin or other&#xD;
             macrolides within 14 days prior to screening.&#xD;
&#xD;
          -  History of allergy (urticarial rash, diffuse erythroderma, serum sickness) to more&#xD;
             than two groups of antibiotics (aminoglycosides, penicillins, cephalosporins,&#xD;
             monobactams, macrolides, or quinolones) that are a therapeutic option.&#xD;
&#xD;
          -  History of anaphylaxis or other life threatening complication to any antibiotic in the&#xD;
             six groups that are a therapeutic option.&#xD;
&#xD;
          -  History of abnormal renal function (serum creatinine &gt; 1.5 x upper limit of normal)&#xD;
             within one year of enrollment.&#xD;
&#xD;
          -  History of abnormal liver function tests (&gt; 2.5 x upper limit of normal) within one&#xD;
             year of enrollment.&#xD;
&#xD;
          -  Clinically documented hearing loss that precludes treatment with aminoglycosides.&#xD;
&#xD;
          -  Post lung transplantation.&#xD;
&#xD;
          -  Positive pregnancy test or female who is lactating or is not practicing an acceptable&#xD;
             method of birth control.&#xD;
&#xD;
          -  Presence of a condition or abnormality that in the opinion of an investigator would&#xD;
             compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          -  Administration of any investigational agent within 30 days prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel M Moskowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane L Burns, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital and Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105-0371</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004 May;42(5):1915-22.</citation>
    <PMID>15131149</PMID>
  </reference>
  <reference>
    <citation>Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother. 2005 Nov;56(5):879-86. Epub 2005 Sep 27.</citation>
    <PMID>16188918</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>March 12, 2008</last_update_submitted>
  <last_update_submitted_qc>March 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2008</last_update_posted>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Antibiotic susceptibility testing</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>Chronic bronchitis</keyword>
  <keyword>Biofilms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
    <mesh_term>Ticarcillin</mesh_term>
    <mesh_term>Ticarcillin-clavulanic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

